Xenetic Biosciences Inc

Company Profile

Xenetic Biosciences Inc had its IPO on 2014-06-30 under the ticker symbol XBIO.

The company operates in the Healthcare sector and Biotechnology industry. Xenetic Biosciences Inc has a staff strength of 4 employees.

Stock update

Shares of Xenetic Biosciences Inc opened at $0.45 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $0.39 - $0.45, and closed at $0.4.

This is a -10.91% slip from the previous day's closing price.

A total volume of 28,444 shares were traded at the close of the day’s session.

In the last one week, shares of Xenetic Biosciences Inc have slipped by -4.76%.

Xenetic Biosciences Inc's Key Ratios

Xenetic Biosciences Inc has a market cap of $6.81 million, indicating a price to book ratio of 0.4335 and a price to sales ratio of 3.6145.

In the last 12-months Xenetic Biosciences Inc’s revenue was $1.71 million with a gross profit of $1.16 million and an EBITDA of $-5746008. The EBITDA ratio measures Xenetic Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Xenetic Biosciences Inc’s operating margin was -393.57% while its return on assets stood at -24.32% with a return of equity of -40.9%.

In Q4, Xenetic Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 46.4%.

Xenetic Biosciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xenetic Biosciences Inc’s profitability.

Xenetic Biosciences Inc stock is trading at a EV to sales ratio of 0.1167 and a EV to EBITDA ratio of 1.0799. Its price to sales ratio in the trailing 12-months stood at 3.6145.

Xenetic Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$14.72 million

Total Liabilities

$1.07 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Xenetic Biosciences Inc ended 2023 with $14.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.72 million while shareholder equity stood at $13.65 million.

Xenetic Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $1.07 million in other current liabilities, 15192.00 in common stock, $-189099618.00 in retained earnings and $0 in goodwill. Its cash balance stood at $13.10 million and cash and short-term investments were $13.10 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Xenetic Biosciences Inc’s total current assets stands at $13.65 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $287360.00 and inventory worth $0.

In 2023, Xenetic Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Xenetic Biosciences Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.4

52-Week High

$1.25

52-Week Low

$0.24

Analyst Target Price

$4

Xenetic Biosciences Inc stock is currently trading at $0.4 per share. It touched a 52-week high of $1.25 and a 52-week low of $1.25. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $0.51 and 200-day moving average was $0.58 The short ratio stood at 1.01 indicating a short percent outstanding of 0%.

Around 1390.5% of the company’s stock are held by insiders while 457.6% are held by institutions.